Medinol is dedicated to the science of cardiovascular intervention. Medinol develops, manufactures, and markets EluNIR, an elastomeric drug-eluting stent made from a thin cobalt-chrome alloy and recognized for its optimal balance between flexibility, conformability, scaffolding, and low metal footprint. EluNIR offers a new level of uniform drug elution and surface quality and demonstrated excellent clinical outcomes and long-term safety profile in clinical studies.
EluNIR features the novel Flexx catheter technology with a visible metallic spring tip that eliminates tip flare-out and buckling. Flexx overcomes standard polymer tip limitations, offering both superb flexibility and uncompromised crossability, resulting in unprecedented ease of delivery even in complex anatomies.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Medinol Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Sep 13, 2022
www.prnewswire.com
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
#Customers #Partners
Jan 6, 2020
www.massdevice.com
Medinol stent performs just as well as Medtronic Resolute, study says
#Partners #Customers
Jan 11, 2018
www.cardiovascularbusiness.com
Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent
#Customers
Dec 4, 2017
www.globes.co.il
FDA approves Medinol's medicated stent
#Customers #Partners
Nov 30, 2017
www.prnewswire.com
Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System